"The management of advanced prostate cancer has evolved significantly, driven in part by the integration of diverse biomarkers that guide treatment decisions from diagnosis through progression," says Nedim Ruhotina, MD.
Nedim Ruhotina, MD
Advertisement
Articles by Nedim Ruhotina, MD
Advertisement
Latest Updated Articles
Biomarkers in advanced prostate cancer: Liquid biopsy, ctDNA, and moreFebruary 10th 2025
Advertisement
Advertisement
Trending on Urology Times
1
Study suggests potential diuretic effect with nadofaragene firadenovec
2
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
3
Praful Ravi, MB, BChir, MRCP, on PSMA-PET during initial systemic therapy for mHSPC
4
Published data show DFS benefit with aglatimagene besadenovec in localized prostate cancer
5